

Pediatric Formulation Development – Industry Perspective on Palatability Challenges & Opportunities

Jeremy A. Bartlett, Ph.D.

Pfizer Inc.


Pharmaceutical Sciences

Drug Product Design

Groton, CT USA

Email: jeremy.a.bartlett@pfizer.com

Phone: (860) 715-2598



Challenges and Strategies to Facilitate Formulation Development of
Pediatric Drug Products

CERSI Workshop in collaboration with EuPFI & IQ Consortium

Hyattsville, MD

June 8-9, 2016



WORLDWIDE RESEARCH & DEVELOPMENT
PharmaTherapeutics Pharmaceutical Sciences

Acknowledgements

Pfizer UK

- Cram, Anne
 - EuPFI
- Coupe, Alastair
 - Innovate UK Pediatric Consortium
- Bennett, Jo
- Carmody, Alan
- McGovern, James
- Contreras, Lourdes
- Turnbull, Neil
- English, Cheryl
- Ogilvie, Ron
- Simmons, Joanna
- Forbes, Claire

Pfizer US

- Santangelo, Matt
- Herbig, Scott M
- Shanker, Ravi M
- Heimlich, John H
- Hausberger, Angie

Pfizer US

- Murdande, Sharad
- Prpich, Andrew
- Ciringh, Yangzhen
- Nixon, Phil
- Korsmeyer, Richard
- Thombre, Avi
- Sagawa, Kazuko

Pfizer Global Pediatric Center of Excellence

- Thompson, Charlie
- Darsey, Edress

Institute of Pediatric Innovation (IPI)

Others I am sure I have missed...



Outline

- **Why is palatability important?**
- **What makes developing a palatable formulation challenging?**
- **What can be done?**

Why is palatability important?



Bartlett Household Example 1



WORLDWIDE RESEARCH & DEVELOPMENT
PharmaTherapeutics Pharmaceutical Sciences

Why is palatability important?

Bartlett Household Example 2



WORLDWIDE RESEARCH & DEVELOPMENT
PharmaTherapeutics Pharmaceutical Sciences

Why is Taste of Medicines Important?

- **Even the best medicine won't work unless the child takes it!**
- **A 2003 survey of pediatricians conducted by the American Association of Pediatrics found**
 - Unpleasant taste was the biggest barrier for completing treatments in pediatrics¹
- **Average **compliance rate** in children is ~58%, with major factors attributed to formulation and palatability²**

¹Ayenew, Z., V. Puri, L. Kumar and A. K. Bansal (2009). "Trends in pharmaceutical taste masking technologies: a patent review." Recent Pat. Drug Delivery Formulation **3**(1): 26-39.

²Matsui, D. (2007). "Current issues in pediatric medication adherence." Paediatr Drugs **9**(5): 283-288.

Outline

- Why is palatability important?
- **What makes developing a palatable formulation challenging?**
- What can be done?


Challenges in developing pediatric formulations

- **Diverse patient group**
 - Birth to age ~ 18
 - Size/Weight change over 20 fold
 - Dose adjustment >3-4 fold
 - Ability to take and preference of dosage form varies across the wide age range
- **Palatability**
 - Cultural and geographical preferences
 - Restrictions related to use of excipients (type and quantity)
 - Taste assessment vs. compliance
 - How do you know when you are “good enough?”
 - What palatability information should you use to drive formulation development?
 - Adult Healthy Volunteers
 - Trained Adult Taste Panel
 - Pediatric Patients
 - In vitro
- **Keeping in mind, palatability is only one part of dosage form acceptability!**

Outline

- Why is palatability important?
- What makes developing a palatable formulation challenging?
- **What can be done?**

Pediatric Oral Dosage Form Decision Tree



Pediatric Dosage Form Technologies: Small Molecule Pediatric Products -- oral



Ready to Use (RTU) Oral Solution or Oral Suspension

Dosed using a syringe, dosing cup, or dosing spoon

Powder for Oral Solution or Powder for Oral Suspension (POS)



Constituted with water by the Pharmacist

Dosed using a syringe, dosing cup, or dosing spoon

Being
implemented!



Taste-masked Microspheres

- Prevent drug release until the microspheres clear the mouth – achieve “taste neutral” profile
- Spherical coated multiparticulates
- Stability in Zone 4 (global)
- Reduce/Eliminate the need for flavors, sugars, preservatives
- Packaging include bottles, sachet, capsules (other presentations are also possible)
- Potential dosing with or without water



Pediatric Multiparticulate Platform Summary

- **Oral Multiparticulates provide an excellent platform for pediatric medicines**
 - Ideal substrate for taste masking
 - Dose Flexibility
 - Reduce/Eliminate need for preservatives, sweeteners, flavorants, dyes, etc
 - May be dosed w/wo water
- **To be successful three main focus areas**
 - a) Multiparticulate
 - b) Barrier Coating
 - c) Dosing and Administration, Device/Packaging
 - Running Open Innovation Challenge to generate ideas on the best way to accurately dispense and administer the multiparticulates



Institute of Pediatric Innovation and Pfizer collaborate on open innovation pediatric device challenge

System for Dosing and Dispensing Multiparticulate Formulations of Pediatric Drugs Request for Proposals (RFP)



The Institute for Pediatric Innovation (IPI) and Pfizer are collaborating on an open innovation challenge to solicit and support innovative ideas for a system consisting of a package and dispensing device that will be used to deliver oral solid multiparticulate (MP) medicines to children. Parties entering the competition including the winning entity will retain ownership of related intellectual property, as Pfizer and IPI intend that the party submitting the winning design commercialize the design independently either directly or through a partner. The organization who submits the winning design will be awarded a seed grant to fund 'proof of concept' steps toward development of the device, and will have the opportunity for ongoing liaison with IPI to access its networks to explore follow-on funding opportunities.

Pfizer has developed a formulation technology that addresses taste, storage, and other factors essential for safe, accurate, and adherent administration of medicines to children in low-resource global health settings

Expect to announce awardee ~ August 2016

www.pfizer.com/responsibility/grants_contributions/device_challenge



WORLDWIDE RESEARCH & DEVELOPMENT
PharmaTherapeutics Pharmaceutical Sciences

About the
Challenge

Request for
Proposal/Timeline

About the
Collaborators

Contact Us

What do we want to achieve?

We welcome proposals for the design of a device that can measure and administer a drug multiparticulate formulation in a child friendly but child-misuse resistant format and in doses relevant for therapy in low resource settings

Which expertise do we seek?

We seek ideas from individuals or groups who understand the challenges of the low resource setting and are eager to address these challenges with their device design. We are looking for people with experience in, but not limited to, device design, drug dispensing, and human factors design. We believe that "less is more" and that we can minimize device complexity while maximizing device utility.

What are the evaluation criteria?

A review committee, led by IPI and composed of engineers, end users, and experts, will make decisions on which proposals will receive funding. Grant funding will be provided by Pfizer. Up to \$50,000 is available for the award(s).

The proposals will be evaluated on:

1. Dose accuracy
2. Cost
3. End user ease of use
4. Cultural appropriateness

Conclusions & Opportunities

- Connecting taste assessment evaluations with compliance data would be very helpful
- Providing taste evaluation feedback early in adult clinical development can help guide technology selection
- Oral Multiparticulates provide an excellent platform for pediatric medicines
- Still working on –
 - What is the “ideal” barrier membrane?
 - What is the “best” way to dispense and administer a free flowing, non gritty, tasteless powder?